267 related articles for article (PubMed ID: 30654190)
1. Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System.
Moses C; Nugent F; Waryah CB; Garcia-Bloj B; Harvey AR; Blancafort P
Mol Ther Nucleic Acids; 2019 Mar; 14():287-300. PubMed ID: 30654190
[TBL] [Abstract][Full Text] [Related]
2. Programmable activation of Bombyx gene expression using CRISPR/dCas9 fusion systems.
Wang XG; Ma SY; Chang JS; Shi R; Wang RL; Zhao P; Xia QY
Insect Sci; 2019 Dec; 26(6):983-990. PubMed ID: 30088341
[TBL] [Abstract][Full Text] [Related]
3. A novel fungal gene regulation system based on inducible VPR-dCas9 and nucleosome map-guided sgRNA positioning.
Schüller A; Wolansky L; Berger H; Studt L; Gacek-Matthews A; Sulyok M; Strauss J
Appl Microbiol Biotechnol; 2020 Nov; 104(22):9801-9822. PubMed ID: 33006690
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-assisted transcription activation by phase-separation proteins.
Liu J; Chen Y; Nong B; Luo X; Cui K; Li Z; Zhang P; Tan W; Yang Y; Ma W; Liang P; Songyang Z
Protein Cell; 2023 Dec; 14(12):874-887. PubMed ID: 36905356
[TBL] [Abstract][Full Text] [Related]
5. Targeted CRISPR activation is functional in engineered human pluripotent stem cells but undergoes silencing after differentiation into cardiomyocytes and endothelium.
Karbassi E; Padgett R; Bertero A; Reinecke H; Klaiman JM; Yang X; Hauschka SD; Murry CE
Cell Mol Life Sci; 2024 Feb; 81(1):95. PubMed ID: 38372898
[TBL] [Abstract][Full Text] [Related]
6. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.
Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P
Oncotarget; 2016 Sep; 7(37):60535-60554. PubMed ID: 27528034
[TBL] [Abstract][Full Text] [Related]
7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
8. Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.
Prvanović M; Nedeljković M; Tanić N; Tomić T; Terzić T; Milovanović Z; Maksimović Z; Tanić N
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833123
[TBL] [Abstract][Full Text] [Related]
9. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
[TBL] [Abstract][Full Text] [Related]
10. Enabling Graded and Large-Scale Multiplex of Desired Genes Using a Dual-Mode dCas9 Activator in Saccharomyces cerevisiae.
Deaner M; Mejia J; Alper HS
ACS Synth Biol; 2017 Oct; 6(10):1931-1943. PubMed ID: 28700213
[TBL] [Abstract][Full Text] [Related]
11. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.
Choudhury SR; Cui Y; Lubecka K; Stefanska B; Irudayaraj J
Oncotarget; 2016 Jul; 7(29):46545-46556. PubMed ID: 27356740
[TBL] [Abstract][Full Text] [Related]
13. Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Herkert B; Kauffmann A; Mollé S; Schnell C; Ferrat T; Voshol H; Juengert J; Erasimus H; Marszalek G; Kazic-Legueux M; Billy E; Ruddy D; Stump M; Guthy D; Ristov M; Calkins K; Maira SM; Sellers WR; Hofmann F; Hall MN; Brachmann SM
Cancer Res; 2016 Jan; 76(2):390-402. PubMed ID: 26577700
[TBL] [Abstract][Full Text] [Related]
14. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
15. Gene activation by a CRISPR-assisted
Xu X; Gao J; Dai W; Wang D; Wu J; Wang J
Elife; 2019 Apr; 8():. PubMed ID: 30973327
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
17. RNA-guided transcriptional regulation in planta via synthetic dCas9-based transcription factors.
Piatek A; Ali Z; Baazim H; Li L; Abulfaraj A; Al-Shareef S; Aouida M; Mahfouz MM
Plant Biotechnol J; 2015 May; 13(4):578-89. PubMed ID: 25400128
[TBL] [Abstract][Full Text] [Related]
18. Robust Transcriptional Activation in Plants Using Multiplexed CRISPR-Act2.0 and mTALE-Act Systems.
Lowder LG; Zhou J; Zhang Y; Malzahn A; Zhong Z; Hsieh TF; Voytas DF; Zhang Y; Qi Y
Mol Plant; 2018 Feb; 11(2):245-256. PubMed ID: 29197638
[TBL] [Abstract][Full Text] [Related]
19. Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Fang M; Hutchinson L; Deng A; Green MR
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1250-5. PubMed ID: 26787892
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional activation of fucosyltransferase (FUT) genes using the CRISPR-dCas9-VPR technology reveals potent N-glycome alterations in colorectal cancer cells.
Blanas A; Cornelissen LAM; Kotsias M; van der Horst JC; van de Vrugt HJ; Kalay H; Spencer DIR; Kozak RP; van Vliet SJ
Glycobiology; 2019 Feb; 29(2):137-150. PubMed ID: 30476078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
